Show simple item record

dc.contributor.authorJansen, Marleen E
dc.contributor.authorRigter, T
dc.contributor.authorRodenburg, W
dc.contributor.authorFleur, T M C
dc.contributor.authorHouwink, E J F
dc.contributor.authorWeda, M
dc.contributor.authorCornel, Martina C
dc.date.accessioned2018-01-10T08:38:48Z
dc.date.available2018-01-10T08:38:48Z
dc.date.issued2017
dc.identifier.citationReview of the Reported Measures of Clinical Validity and Clinical Utility as Arguments for the Implementation of Pharmacogenetic Testing: A Case Study of Statin-Induced Muscle Toxicity. 2017, 8:555 Front Pharmacolen
dc.identifier.issn1663-9812
dc.identifier.pmid28878673
dc.identifier.doi10.3389/fphar.2017.00555
dc.identifier.urihttp://hdl.handle.net/10029/621139
dc.description.abstractAdvances from pharmacogenetics (PGx) have not been implemented into health care to the expected extent. One gap that will be addressed in this study is a lack of reporting on clinical validity and clinical utility of PGx-tests. A systematic review of current reporting in scientific literature was conducted on publications addressing PGx in the context of statins and muscle toxicity. Eighty-nine publications were included and information was selected on reported measures of effect, arguments, and accompanying conclusions. Most authors report associations to quantify the relationship between a genetic variation an outcome, such as adverse drug responses. Conclusions on the implementation of a PGx-test are generally based on these associations, without explicit mention of other measures relevant to evaluate the test's clinical validity and clinical utility. To gain insight in the clinical impact and select useful tests, additional outcomes are needed to estimate the clinical validity and utility, such as cost-effectiveness.
dc.language.isoenen
dc.rightsArchived with thanks to Frontiers in pharmacologyen
dc.titleReview of the Reported Measures of Clinical Validity and Clinical Utility as Arguments for the Implementation of Pharmacogenetic Testing: A Case Study of Statin-Induced Muscle Toxicity.en
dc.typeArticleen
dc.identifier.journalFront Pharmacol 2017, 8:555en
html.description.abstractAdvances from pharmacogenetics (PGx) have not been implemented into health care to the expected extent. One gap that will be addressed in this study is a lack of reporting on clinical validity and clinical utility of PGx-tests. A systematic review of current reporting in scientific literature was conducted on publications addressing PGx in the context of statins and muscle toxicity. Eighty-nine publications were included and information was selected on reported measures of effect, arguments, and accompanying conclusions. Most authors report associations to quantify the relationship between a genetic variation an outcome, such as adverse drug responses. Conclusions on the implementation of a PGx-test are generally based on these associations, without explicit mention of other measures relevant to evaluate the test's clinical validity and clinical utility. To gain insight in the clinical impact and select useful tests, additional outcomes are needed to estimate the clinical validity and utility, such as cost-effectiveness.


This item appears in the following Collection(s)

Show simple item record